PET Imaging

Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that enables visualization of metabolic processes in the body. The basics of PET imaging is that the technique detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (also called radiopharmaceuticals, radionuclides or radiotracer). The tracer is injected into a vein on a biologically active molecule, usually a sugar that is used for cellular energy. PET systems have sensitive detector panels to capture gamma ray emissions from inside the body and use software to plot to triangulate the source of the emissions, creating 3-D computed tomography images of the tracer concentrations within the body.

FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018

June 21, 2018 — Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new...

PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018

June 13, 2018 — A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine...

Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018

June 5, 2018 — The U.S. Food and Drug Administration (FDA) has cleared the Biograph Vision, a new...

News | Computed Tomography (CT) | May 21, 2018

May 21, 2018 — The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation...

PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018

May 17, 2018 — A novel positron emission...

PET Imaging Shows Protein Clumping May Contribute to Heart Failure Development
News | PET Imaging | May 11, 2018

May 11, 2018 — A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to...

News | Radiopharmaceuticals and Tracers | May 09, 2018

May 9, 2018 — Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a...

Novel PET Agent Could Help Guide Therapy for Brain Diseases

Rat brain 11C‐Me‐NB1 PET images (0‐60 min) superimposed on an MRI template. Credit: SD Krämer et al., ETH Zurich, Zurich, Switzerland

News | PET Imaging | April 10, 2018

April 10, 2018 — Researchers have developed a new imaging agent that could help guide and assess treatments for...

Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018

March 8, 2018 – Doctors contemplating the best therapy for...

In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows).

In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows). Image courtesy of A Piccardo et al., Galliera Hospital, Genoa, Italy.

News | Prostate Cancer | March 07, 2018

An Italian study featured in the March...

Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018

February 21, 2018 — Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the...

PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018

February 5, 2018 — Using nuclear...

PET Tracer Measures Damage From Multiple Sclerosis in Mouse Models
News | PET Imaging | January 24, 2018

January 24, 2018 — The loss or damage of myelin, a cellular sheath that surrounds and insulates nerves, is the...

Novel PET Tracer Clearly Identifies and Tracks Bacterial Lung Infection

Representative PET/CT images of 18F-FDS and 18F-FDG in inflamed mice. Mice were inoculated with dead K. pneumoniae (10^8 CFU/mL). Imaging was performed for days 1, 2, 3 and 4 using 18F-FDG and 18F-FDS. CT images showed clear inflammation on day 2 and day 3 with corresponding high 18F-FDG uptake on PET. No significant uptake of 18F-FDS was detected for any of those 4 days. Credit: J Li et al., University of Louisville School of Medicine, Louisville, Ky.

News | PET-CT | January 22, 2018

January 22, 2018 — Researchers at the University of Louisville, Kentucky, have demonstrated that a new...

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017

December 28, 2017 — In the December featured basic science article in...

Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017

October 27, 2017 — The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a...

SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017

October 25, 2017 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use...

Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017

October 4, 2017 — Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an...

News | Radiology Business | September 19, 2017

September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development,...

Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017

September 18, 2017 — Toshiba Medical announced that it will display several new enhancements to its existing...

Overlay Init